ArticleCell death & disease2020

Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.

Francesco Dituri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.